目的：系统比较康柏西普和雷珠单抗治疗视网膜静脉阻塞继发黄斑水肿(RVO-ME)的疗效和安全性，为临床指导用药提供依据。

方法：全网综合检索关于玻璃体腔内注射康柏西普和雷珠单抗治疗RVO-ME的临床随机对照试验文献，对纳入文献进行风险评估，并提取相关数据指标。采用RevMan 5.3软件进行数据分析，并采用Egger检验评价发表偏倚。

结果：本研究纳入文献14 篇，共计 1 350眼。康柏西普组和雷珠单抗组患者最佳矫正视力(BCVA)在治疗后2wk，2、3、6mo无明显差异，但在治疗后1wk[WMD=-0.03，95% CI(-0.05，-0.02)，P<0.0001]和1mo[WMD= -0.03，95% CI(-0.04，-0.01)，P=0.001]康柏西普组患者BCVA相比雷珠单抗组较好。两组患者黄斑中心凹视网膜厚度(CMT)在治疗后1、2wk，1、2、3mo无明显差异，但在治疗后6mo\康柏西普组患者黄斑水肿减轻程度相比雷珠单抗组更明显。玻璃体腔内注射康柏西普和雷珠单抗产生的不良反应情况无差异[OR=0.95，95% CI(0.57，1.57)，P=0.84]，但康柏西普的平均注射次数较少。

结论：康柏西普和雷珠单抗均可改善BCVA，降低CMT，二者在后期视力改善方面无差异，但康柏西普在改善CMT方面更具优势，且注射次数少，费用低。

METHODS: The Cochrane Library, Embase, Web of Science, and CNKI, Wanfang data, and VIP database were comprehensively searched for studies comparing conbercept versus ranibizumab in patients with RVO-ME. Best-corrected visual acuity(BCVA), central macular thickness(CMT), intraocular pressure(IOP), mean number of intravitreal injections and adverse events were extracted from the final eligible studies. RevMan 5.3 software was used for relevant index data analysis. Random and fixed effect models were employed to evaluate heterogeneity and the publication bias.

RESULTS: A total of 14 randomized controlled trial(RCT)studies, involving 1 350 eyes. There was no significant difference in BCVA improved between the two groups after treatment 2wk, 2mo, 3mo and 6mo, but there was significant difference in BCVA improved after treatment 1wk [WMD=-0.03; 95% CI(-0.05, -0.02); P<0.0001] and 1mo [WMD=-0.03; 95% CI(-0.04, -0.01); P=0.001]. The conbercept treatment group had higher CMT reduction compared with ranibizumab treatment group after 6mo treatment, and there was a significant difference [WMD=-28.77; 95% CI(-54.23, -3.31); P=0.03], and there were no significant difference between two groups in others period of time. There were no significant difference in intraocular pressure(IOP)and adverse events between the two groups [OR=0.95; 95% CI(0.57, 1.57); P=0.84]. However, the use of conbercept had a fewer mean number of injections.

CONCLUSION: CMT and BCVA were improved significantly both in the conbercept and ranibizumab groups. Compared with ranibizumab, conbercept group did not have greater improved BCVA, but with a more CMT reduction after 6mo. The advantage of conbercept is fewer injections and maybe it is better for treatment of RVO-ME.